DRUG LEGALIZATION SERIES
PART 9
If you’re new to the series, start here.

What would regulation and a drug regulation framework look like?

The question everyone skips

“Legalize drugs” is a slogan.

“What does regulation actually look like?” is policy.

And if you’ve been following along, this Part 9 is the “show your work” post. Earlier parts make the case for why prohibition fails and why the status quo produces predictable harm (especially Part 8 on fear-based policy), but none of that matters if the alternative is hand-waving. So this post does the practical thing: it lays out what a risk-based drug regulation system looks like in real operational terms.

The framework in this post is:

• Tiered by risk (not one channel for every drug)

• Built around a regulated supply chain

• Grounded in enforceable standards (not vibes)

• Measurable by public safety outcomes

• Integrated with harm reduction and recovery infrastructure

Prohibition is the baseline we’re comparing to

Before designing anything, get clear about what we’re replacing.

The overdose crisis is not happening inside a regulated system. It’s happening inside a supply chain that is, by definition, unregulated.

• In 2024, the U.S. recorded 79,384 drug overdose deaths (final mortality data). [1]

• In 2023, there were 105,007 drug overdose deaths. [1]

• In 2022, there were 107,941 drug overdose deaths. [2]

So the right comparison is not “regulation has risks” versus “no risks.”

The real comparison is:

Can a risk-based drug regulation system reduce harm relative to the prohibition system that produced ~100,000+ annual deaths? [1][2]

Regulation is not decriminalization (and it isn’t “anything goes”)

A serious drug regulation framework starts with definitions:

• Prohibition bans production and sale, pushing supply into an illicit market with no enforceable standards.

• Decriminalization changes penalties for possession, but does not automatically govern how drugs are produced, tested, labeled, priced, or distributed.

• Regulation governs supply: licensing, product standards, pricing strategy, enforcement priorities, and outcome measurement.

For a historical reminder of how “ban it” can collide with enforcement burdens and noncompliance—and why countries shift toward regulation—see the National Archives’ overview of temperance and Prohibition-era policy history. [3]

That history isn’t a perfect analogy to modern drugs. It’s a reminder that policy choices determine whether the state governs the market or the market governs the state.

A tiered model by risk

The core of risk-based drug regulation is “right channel for the risk.”

Not all drugs belong in the same access channel. A workable model tiers restrictions using factors like:

• Overdose risk / acute toxicity

• Dependence risk and withdrawal severity

• Impairment risk (especially driving)

• Externalities (public disorder, infectious disease risk, violence)

• Whether supervision materially reduces harm

• Whether standardized dosing and purity testing change outcomes

Tier 1: Lower-risk retail regulation (cannabis-style mechanics)

This tier fits substances where harms can be meaningfully reduced with consumer-product guardrails: licensing, testing, labeling, age limits, packaging standards, purchase limits, and auditing.

Cannabis legalization is the clearest U.S. example of how a regulated supply chain functions. It’s not “no enforcement.” It’s enforceable regulation.

Potency limits (real examples):

• Washington limits edible servings to 10 mg active delta‑9 THC and packages to 100 mg active delta‑9 THC. [4]

• Colorado caps individually packaged edible products at 100 mg total active THC. [5]

• Oregon has adjusted edible limits through rule changes; official OLCC program bulletins describe a move to 10 mg per serving / 100 mg per package for adult-use edibles effective April 1, 2022 (with prior lower limits). [6]

Those are not “guidelines.” Those are enforceable controls.

Why this matters: you can’t impose or enforce potency standards in an illicit market. Regulation makes dose governable.

Tier 2: Supervised services regulation (channel design for moderate-to-higher risk)

Some substances should not be sold like consumer packaged goods.

A risk-based drug regulation model uses supervised services when setting and oversight meaningfully reduce harm.

Oregon’s psilocybin program is a U.S. example of this logic: regulated licensing and standards for service settings rather than a simple retail model. [7]

Tier 3: Medicalized distribution for highest-risk substances

For drugs with high overdose risk and high dependence potential, the goal is not “normalization.” The goal is survival, stabilization, and exit ramps.

The U.S. already runs a proof-of-concept system here: opioid treatment programs (OTPs).

• Federal regulations governing OTPs are laid out in 42 CFR Part 8. [8]

• SAMHSA revised Part 8 and released a final rule in February 2024 (with implementation details and changes summarized on SAMHSA’s site). [9][10]

• The Federal Register contains the final rule publication for the Part 8 updates. [11]

This tier can include:

• restricted channels (licensed medical settings/pharmacies/registered programs)

• controlled dosing and standardized formulations

• strict inventory controls and diversion monitoring

• required linkage into treatment and recovery supports

The supply-control toolkit

If risk tiers are the strategy, supply control is the mechanism. This is where “regulation” becomes real.

A credible regulated supply chain is built from:

• licensing and eligibility rules

• product standards (testing, labeling, recalls)

• inventory and transport controls

• audit power and meaningful penalties

Licensing: who can produce, test, transport, and sell

Licensing is how regulators create leverage.

Under prohibition, the state has zero leverage over producers because they are, by definition, illicit.

A serious licensing structure defines:

• who can participate

• what activities are permitted (production, processing, testing, distribution, retail/service)

• compliance requirements

• penalties and license loss conditions

Testing, labeling, and recalls

Regulation can enforce what prohibition cannot:

• contaminant thresholds

• accurate labeling

• standardized dose units

• batch/lot traceability for recalls

Prohibition can only punish after harm occurs. Regulation can prevent predictable harm through standards.

Seed-to-sale tracking system (diversion control)

A legal market that leaks into an illegal market is unstable.

A seed-to-sale tracking system creates an auditable inventory trail.

Colorado’s rules define an “Inventory Tracking System” as a required seed-to-sale system that tracks retail marijuana from the seed/immature plant stage until it is sold to a consumer or destroyed. [12] Colorado’s rules also explicitly state the purpose: tracking regulated marijuana from genetic material stage until sale or destruction. [13]

That’s what “supply control” means operationally: auditable inventory and enforceable reporting.

Guardrails the public can see

Regulation earns legitimacy by constraining harm with visible rules.

Age limits and access controls

A regulated channel creates leverage for ID checks and compliance enforcement.

A serious model also includes:

• purchase limits

• restricted hours/locations

• advertising and youth-marketing bans

• compliance checks with meaningful license consequences

Packaging standards (including child-resistant packaging)

Child-resistant packaging isn’t performative. It’s baseline consumer safety.

The U.S. Consumer Product Safety Commission explains that the Poison Prevention Packaging Act (PPPA) requires certain substances to use “special packaging” designed to be significantly difficult for children under five to open. [14]

A credible regulatory model uses child-resistant packaging and anti-child-attractive product rules—especially for ingestibles.

Potency limits and product-format controls

Potency limits are not magic. They don’t eliminate harm.

They do something more realistic: they make dose governable.

Washington, Colorado, and Oregon’s rule structures show how states can cap servings and package totals for edibles and require dose standardization. [4][5][6]

Pricing and taxation: fund the system without pricing people back into the illicit market

If legal pricing is too high, illegal supply stays competitive.

Tax policy is not just revenue. It’s a public safety tool.

Examples from cannabis:

• Washington requires retailers to collect a 37% cannabis excise tax on retail sales. [15]

• Oregon imposes a 17% state marijuana tax, with local taxes up to 3% if approved by voters. [16]

• Colorado applies a 15% retail marijuana excise tax. [17]

• Colorado also applies a 15% state retail marijuana sales tax on retail marijuana and retail marijuana products. [18]

A risk-based approach treats pricing as a lever:

• fund oversight and enforcement priorities

• fund harm reduction integration and recovery infrastructure

• avoid “price cliffs” that hand the market back to unlicensed sellers

• consider risk-adjusted taxes (discourage higher-harm formats without collapsing the legal market)

Enforcement priorities under regulation

Regulation does not eliminate enforcement.

It changes what gets targeted.

A drug regulation framework should prioritize enforcement against:

• unlicensed production and sales

• diversion and tracking manipulation

• fraud, mislabeling, contamination

• sales to minors

• impaired driving and violence

This is not “soft.” It’s precise.

It also reduces the “easy arrests” trap—where possession becomes the default enforcement target because it’s simple, while organized supply adapts.

Harm reduction integration and recovery infrastructure aren’t optional

Regulation without exits will fail.

CDC describes harm reduction as practical strategies to reduce negative consequences of drug use and connect people to care—including interventions like naloxone distribution, syringe services, and linkage to treatment. [19]

Meanwhile, federal OTP rules explicitly define treatment in a comprehensive way—medication plus services and supports—not just a prescription. [8][9]

A durable model builds the care layer into regulation:

• treatment access on demand (MOUD capacity, retention support)

• stabilization supports (housing, navigation, mental health)

• reentry support (employment, continuity of care)

• measured outcomes and public dashboards

This connects directly back to earlier parts of the series: if funding and infrastructure aren’t real, the system collapses into backlash politics.

Metrics: how regulation proves it works

If reform is real, it measures outcomes and publishes them.

At minimum, a public dashboard should track:

• Overdose deaths and nonfatal overdoses (baseline and trend). [1]

• Youth use and access indicators (prevalence and perceived access). Colorado’s 2023 Healthy Kids Survey reports 13% past-month marijuana use among youth. [20]

• Crime trends (violent and property crime, with careful causal claims). NIJ hosts a time-series analysis of crime in Colorado and Washington in relation to cannabis legalization. [21]

• Supply integrity: diversion cases, audit findings, recalls, unlicensed market indicators. [12][13]

• Treatment access and retention: wait times, MOUD uptake, continuity of care. [8][9]

Regulation stays legitimate by publishing data and adjusting rules when outcomes drift.

Portugal, briefly (and we’ll go deeper later)

Portugal is often invoked in U.S. debates—often inaccurately.

Portugal’s signature move was decriminalizing use and possession while shifting toward a health-led approach and expanding treatment/harm reduction. Peer-reviewed reviews emphasize that outcomes are tied to the broader health and service architecture, not a single magic policy lever. [22]

We’ll explore Portugal in more detail later in the series. For Part 9, the relevant takeaway is narrower:

Channel design and service capacity matter more than slogans.

If you want to follow the full series as it publishes, visit the blog.
If you prefer audio conversations on recovery, reentry, and purpose, check the podcast page.
And if you want the longer story behind why I write about this, start here.

FAQ

What does “risk-based drug regulation” mean in plain English?

It means different access channels and restrictions based on risk. Lower-risk substances can be governed through licensed adult retail rules. Higher-risk substances may require supervised services or medicalized distribution. [4][8]

How is a drug regulation framework different from decriminalization?

A drug regulation framework governs supply (licensing, standards, audits, pricing, enforcement priorities). Decriminalization primarily reduces criminal penalties for possession and does not automatically create a regulated supply chain with testing, labeling, and diversion controls. [3][12]

What are real examples of potency limits in U.S. rules?

Washington caps edible servings at 10 mg active delta‑9 THC and packages at 100 mg. [4] Colorado caps individually packaged edible products at 100 mg total active THC. [5] Oregon rule updates and program bulletins describe an adult-use edible limit structure that includes 10 mg servings and 100 mg packages. [6]

What is a seed-to-sale tracking system and why does it matter?

It is an inventory and compliance system that tracks regulated product through the supply chain to reduce diversion and support audits and recalls. Colorado defines its Inventory Tracking System as a required seed-to-sale system and states its tracking purpose in regulation. [12][13]

Does regulation eliminate enforcement?

No. It focuses enforcement on unlicensed activity, diversion, fraud, contamination, sales to minors, impaired driving, and violence—rather than blanket criminalization and possession-first policing. [12][13]

Why must harm reduction integration and recovery infrastructure be part of regulation?

Because public safety requires preventing death and stabilizing people who are already using drugs. CDC defines harm reduction as practical strategies that reduce harms and connect people to care. [19] Federal OTP rules and SAMHSA guidance frame treatment as comprehensive services and safeguards, not punishment. [8][9]

References

[1] CDC National Center for Health Statistics. “Drug Overdose Deaths in the United States, 2023–2024.” https://www.cdc.gov/nchs/products/databriefs/db549.htm

[2] CDC National Center for Health Statistics. “Drug Overdose Deaths in the United States, 2002–2022.” (Data Brief) https://www.cdc.gov/nchs/data/databriefs/db491.pdf

[3] U.S. National Archives. “Spirited Republic: Alcohol, Temperance, and Prohibition.” https://www.archives.gov/publications/prologue/2014/winter/spirited-republic

[4] Washington Administrative Code. “WAC 314-55-095: Cannabis servings and transaction limits.” https://app.leg.wa.gov/wac/default.aspx?cite=314-55-095

[5] Cornell Law School, Legal Information Institute. “1 CCR 212-3-6-310 — THC Content Container Restriction (Colorado).” https://www.law.cornell.edu/regulations/colorado/1-CCR-212-3-6-310

[6] Oregon Liquor and Cannabis Commission (OLCC). “Recreational Marijuana Program — Information Bulletin.” (THC potency changes; adult-use edible limits effective April 1, 2022) https://lawapps2.law.miami.edu/clink/download?ca_id=2052&cad_id=3103

[7] Oregon Health Authority. “Oregon Psilocybin Services.” https://www.oregon.gov/oha/ph/preventionwellness/pages/oregon-psilocybin-services.aspx

[8] Electronic Code of Federal Regulations (eCFR). “42 CFR Part 8 — Medications for the Treatment of Opioid Use Disorder.” https://www.ecfr.gov/current/title-42/chapter-I/subchapter-A/part-8

[9] SAMHSA. “42 CFR Part 8 Final Rule.” https://www.samhsa.gov/substance-use/treatment/opioid-treatment-program/42-cfr-part-8

[10] SAMHSA. “The 42 CFR Part 8 Final Rule — Table of Changes.” https://www.samhsa.gov/substance-use/treatment/opioid-treatment-program/42-cfr-part-8/changes

[11] Federal Register. “Medications for the Treatment of Opioid Use Disorder.” (Final rule) https://www.federalregister.gov/documents/2024/02/02/2024-01693/medications-for-the-treatment-of-opioid-use-disorder

[12] Colorado Secretary of State. “Code of Colorado Regulations: 1 CCR 212-2.” (Inventory Tracking System definition; seed-to-sale tracking) https://www.sos.state.co.us/CCR/GenerateRulePdf.do?fileName=1+CCR+212-2&ruleVersionId=5977

[13] Cornell Law School, Legal Information Institute. “1 CCR 212-3-3-805 — Inventory Tracking System (purpose and tracking scope).” https://www.law.cornell.edu/regulations/colorado/1-CCR-212-3-3-805

[14] U.S. Consumer Product Safety Commission. “Poison Prevention Packaging Act (PPPA) Business Guidance.” https://www.cpsc.gov/Business–Manufacturing/Business-Education/Business-Guidance/PPPA

[15] Washington Department of Revenue. “Cannabis retailers.” (37% cannabis excise tax) https://dor.wa.gov/taxes-rates/taxes-due-cannabis/cannabis-retailers

[16] Oregon Department of Revenue. “Marijuana: Businesses.” (17% state tax; local up to 3%) https://www.oregon.gov/dor/programs/businesses/pages/marijuana.aspx

[17] Colorado Department of Revenue. “Marijuana Excise Tax.” (15% excise tax) https://tax.colorado.gov/marijuana-excise-tax

[18] Colorado Department of Revenue. “Marijuana Sales Tax.” (15% retail marijuana sales tax) https://tax.colorado.gov/marijuana-sales-tax

[19] CDC. “OD2A Case Study: Harm Reduction.” https://www.cdc.gov/overdose-prevention/php/od2a/harm-reduction.html

[20] Colorado Department of Public Health & Environment (CDPHE). “2023 Healthy Kids Colorado Survey Results.” https://cdphe.colorado.gov/healthy-kids-colorado-survey-information/2023-healthy-kids-colorado-survey-results

[21] National Institute of Justice. “The Cannabis Effect on Crime: Time-Series Analysis of Crime in Colorado and Washington State.” https://nij.ojp.gov/library/publications/cannabis-effect-crime-time-series-analysis-crime-colorado-and-washington-state

[22] Ximene, R., et al. “20 years of Portuguese drug policy — developments, challenges and the quest for human rights.” (Peer-reviewed; open access via PubMed Central) https://pmc.ncbi.nlm.nih.gov/articles/PMC8285857/

Previous                                                                                                                                                 Next